Adva 27a
Alternative Names: Adva-27aLatest Information Update: 15 Apr 2024
At a glance
- Originator Advanomics
- Developer NOX Pharmaceuticals
- Class Antineoplastics; Dioxanes; Dioxolanes; Lactones; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Small cell lung cancer; Uterine cancer
- Suspended Pancreatic cancer
Most Recent Events
- 31 Dec 2023 Suspended - Preclinical for Pancreatic cancer in USA, Canada (IV)
- 02 Nov 2023 Sunshine Biopharma terminates the research agreement with Jewish General Hospital for Adva 27a
- 13 Feb 2023 Sunshine Biopharma, Jewish General Hospital and McGill University enter into a research agreement to advance the development of Adva 27a